{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:45:32Z","timestamp":1778507132415,"version":"3.51.4"},"reference-count":94,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : The current treatment of choice for peritoneal carcinomatosis from gastric cancer is systemic chemotherapy. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a new aggressive form of loco-regional treatment that is currently being used in pseudomyxoma peritoneii, peritoneal mesothelioma and peritoneal carcinomatosis from colorectal cancer. It is still under investigation for its use in gastric cancer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : The literature between 1970 and 2016 was surveyed systematically through a review of published studies on the treatment outcomes of CRS and HIPEC for peritoneal carcinomatosis from gastric cancer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : Seventeen studies were included in this review. The median survival for all patients ranged from 6.6 to 15.8 months. The 5-years overall survival ranged from 6 to 31%. For patients with complete cytoreduction, the median survival was 11.2 to 43.4 months and the 5-years overall survival was 13\u2006% to 23%. Important prognostic factors were found to be a low peritoneal carcarcinomatosis index (PCI) score and the completeness of cytoreduction.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : The current evidence suggests that CRS and HIPEC has a role to play in the treatment of peritoneal carcinomatosis from gastric cancer. Long term survival has been shown for a select group of patients. However, further studies are needed to validate these results.\n                  <\/jats:p>","DOI":"10.1515\/pp-2016-0010","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T06:16:25Z","timestamp":1465452985000},"page":"67-77","source":"Crossref","is-referenced-by-count":21,"title":["Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review"],"prefix":"10.1515","volume":"1","author":[{"given":"Claramae Shulyn","family":"Chia","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, National Cancer Centre Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramakrishnan Ayloor","family":"Seshadri","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Cancer Institute (WIA), Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahan","family":"Kepenekian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Vaudoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Passot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"2025120909210682132_j_pp-2016-0010_ref_001_w2aab3b7b4b1b6b1ab1b7b1Aa","unstructured":"1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GOLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 11. [Internet] Lyon, France. International Agency for Research on Cancer 2013."},{"key":"2025120909210682132_j_pp-2016-0010_ref_002_w2aab3b7b4b1b6b1ab1b7b2Aa","doi-asserted-by":"crossref","unstructured":"2. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric adenocarcinoma. Br J Surg 2000;87(2):236\u201342.","DOI":"10.1046\/j.1365-2168.2000.01360.x"},{"key":"2025120909210682132_j_pp-2016-0010_ref_003_w2aab3b7b4b1b6b1ab1b7b3Aa","doi-asserted-by":"crossref","unstructured":"3. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 2014 Feb 1;134(3):622\u20138.","DOI":"10.1002\/ijc.28373"},{"key":"2025120909210682132_j_pp-2016-0010_ref_004_w2aab3b7b4b1b6b1ab1b7b4Aa","unstructured":"4. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, et al. Survival of metastatic gastric cancer: Significance of age, sex and race\/ethnicity. J Gastrointest Oncol 2011;2:77\u201384."},{"key":"2025120909210682132_j_pp-2016-0010_ref_005_w2aab3b7b4b1b6b1ab1b7b5Aa","doi-asserted-by":"crossref","unstructured":"5. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010 Mar 17;(3):CD004064.","DOI":"10.1002\/14651858.CD004064.pub3"},{"key":"2025120909210682132_j_pp-2016-0010_ref_006_w2aab3b7b4b1b6b1ab1b7b6Aa","doi-asserted-by":"crossref","unstructured":"6. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012 May 1;30(13):1513\u201318.","DOI":"10.1200\/JCO.2011.39.4585"},{"key":"2025120909210682132_j_pp-2016-0010_ref_007_w2aab3b7b4b1b6b1ab1b7b7Aa","doi-asserted-by":"crossref","unstructured":"7. Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 2013 Nov;24(11):2850\u20134.","DOI":"10.1093\/annonc\/mdt351"},{"key":"2025120909210682132_j_pp-2016-0010_ref_008_w2aab3b7b4b1b6b1ab1b7b8Aa","doi-asserted-by":"crossref","unstructured":"8. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of flourouracil, epidoxorubicin and methotrexate(FEMTX) plus supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71(3):587\u201391.","DOI":"10.1038\/bjc.1995.114"},{"key":"2025120909210682132_j_pp-2016-0010_ref_009_w2aab3b7b4b1b6b1ab1b7b9Aa","doi-asserted-by":"crossref","unstructured":"9. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989 Jan 15;63(2):364\u20137.","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V"},{"key":"2025120909210682132_j_pp-2016-0010_ref_010_w2aab3b7b4b1b6b1ab1b7c10Aa","doi-asserted-by":"crossref","unstructured":"10. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000 Jan 15;88(2):358\u201363.","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909210682132_j_pp-2016-0010_ref_011_w2aab3b7b4b1b6b1ab1b7c11Aa","doi-asserted-by":"crossref","unstructured":"11. Glimelius B, Ekstr\u00f6m K, Hoffman K, Graf W, Sj\u00f6d\u00e9n PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997 Feb;8(2):163\u20138.","DOI":"10.1023\/A:1008243606668"},{"key":"2025120909210682132_j_pp-2016-0010_ref_012_w2aab3b7b4b1b6b1ab1b7c12Aa","doi-asserted-by":"crossref","unstructured":"12. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25:3205\u20139.","DOI":"10.1200\/JCO.2006.10.4968"},{"key":"2025120909210682132_j_pp-2016-0010_ref_013_w2aab3b7b4b1b6b1ab1b7c13Aa","doi-asserted-by":"crossref","unstructured":"13. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996\u20132004.","DOI":"10.1200\/JCO.2002.08.105"},{"key":"2025120909210682132_j_pp-2016-0010_ref_014_w2aab3b7b4b1b6b1ab1b7c14Aa","doi-asserted-by":"crossref","unstructured":"14. Bilici A. Treatment option in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol 2014 Apr 14;20(14):3905\u201315.","DOI":"10.3748\/wjg.v20.i14.3905"},{"key":"2025120909210682132_j_pp-2016-0010_ref_015_w2aab3b7b4b1b6b1ab1b7c15Aa","doi-asserted-by":"crossref","unstructured":"15. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991\u20137.","DOI":"10.1200\/JCO.2006.06.8429"},{"key":"2025120909210682132_j_pp-2016-0010_ref_016_w2aab3b7b4b1b6b1ab1b7c16Aa","doi-asserted-by":"crossref","unstructured":"16. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line threat meant of advanced gastric cancer(SPIRITS trial): a phase III trial. Lancet Oncol 2008;9(3):215\u201321.","DOI":"10.1016\/S1470-2045(08)70035-4"},{"key":"2025120909210682132_j_pp-2016-0010_ref_017_w2aab3b7b4b1b6b1ab1b7c17Aa","doi-asserted-by":"crossref","unstructured":"17. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376(9742):687\u201397.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2025120909210682132_j_pp-2016-0010_ref_018_w2aab3b7b4b1b6b1ab1b7c18Aa","doi-asserted-by":"crossref","unstructured":"18. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND): a randomized, open label phase 3 trial. Lancet Oncol 2013;14(6):490\u20139.","DOI":"10.1016\/S1470-2045(13)70102-5"},{"key":"2025120909210682132_j_pp-2016-0010_ref_019_w2aab3b7b4b1b6b1ab1b7c19Aa","doi-asserted-by":"crossref","unstructured":"19. Elias D, Go\u00e9r\u00e9 D, Dumont F, Honor\u00e9 C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014 Jan;50(2):332\u201340.","DOI":"10.1016\/j.ejca.2013.09.024"},{"key":"2025120909210682132_j_pp-2016-0010_ref_020_w2aab3b7b4b1b6b1ab1b7c20Aa","doi-asserted-by":"crossref","unstructured":"20. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36\u201341.","DOI":"10.1097\/00000658-198807000-00005"},{"key":"2025120909210682132_j_pp-2016-0010_ref_021_w2aab3b7b4b1b6b1ab1b7c21Aa","doi-asserted-by":"crossref","unstructured":"21. Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990;212:592\u20136.","DOI":"10.1097\/00000658-199011000-00005"},{"key":"2025120909210682132_j_pp-2016-0010_ref_022_w2aab3b7b4b1b6b1ab1b7c22Aa","doi-asserted-by":"crossref","unstructured":"22. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991;15:530\u20135.","DOI":"10.1007\/BF01675656"},{"key":"2025120909210682132_j_pp-2016-0010_ref_023_w2aab3b7b4b1b6b1ab1b7c23Aa","doi-asserted-by":"crossref","unstructured":"23. Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437\u201344.","DOI":"10.1016\/S0039-6060(96)80145-0"},{"key":"2025120909210682132_j_pp-2016-0010_ref_024_w2aab3b7b4b1b6b1ab1b7c24Aa","doi-asserted-by":"crossref","unstructured":"24. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997;79:884\u201391.","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C"},{"key":"2025120909210682132_j_pp-2016-0010_ref_025_w2aab3b7b4b1b6b1ab1b7c25Aa","doi-asserted-by":"crossref","unstructured":"25. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529\u201334.","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.3.CO;2-0"},{"key":"2025120909210682132_j_pp-2016-0010_ref_026_w2aab3b7b4b1b6b1ab1b7c26Aa","doi-asserted-by":"crossref","unstructured":"26. Hirose K, Katayama K, Iida A, Yamaguchi A, Nakagawara G, Umeda S, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology 1999;57:106\u201314.","DOI":"10.1159\/000012016"},{"key":"2025120909210682132_j_pp-2016-0010_ref_027_w2aab3b7b4b1b6b1ab1b7c27Aa","doi-asserted-by":"crossref","unstructured":"27. Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20\u20136.","DOI":"10.1001\/archsurg.139.1.20"},{"key":"2025120909210682132_j_pp-2016-0010_ref_028_w2aab3b7b4b1b6b1ab1b7c28Aa","doi-asserted-by":"crossref","unstructured":"28. Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointestinal Surg 2004;8:454\u201363.","DOI":"10.1016\/j.gassur.2003.12.014"},{"key":"2025120909210682132_j_pp-2016-0010_ref_029_w2aab3b7b4b1b6b1ab1b7c29Aa","doi-asserted-by":"crossref","unstructured":"29. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370\u20135.","DOI":"10.1002\/bjs.4695"},{"key":"2025120909210682132_j_pp-2016-0010_ref_030_w2aab3b7b4b1b6b1ab1b7c30Aa","doi-asserted-by":"crossref","unstructured":"30. Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B, et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single Western center experience. Eur J Surg Oncol 2008;34:1246\u201352.","DOI":"10.1016\/j.ejso.2007.12.003"},{"key":"2025120909210682132_j_pp-2016-0010_ref_031_w2aab3b7b4b1b6b1ab1b7c31Aa","doi-asserted-by":"crossref","unstructured":"31. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370\u20137.","DOI":"10.1245\/s10434-010-1039-7"},{"key":"2025120909210682132_j_pp-2016-0010_ref_032_w2aab3b7b4b1b6b1ab1b7c32Aa","doi-asserted-by":"crossref","unstructured":"32. Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and\/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol 2010;101:457\u201364.","DOI":"10.1002\/jso.21519"},{"key":"2025120909210682132_j_pp-2016-0010_ref_033_w2aab3b7b4b1b6b1ab1b7c33Aa","doi-asserted-by":"crossref","unstructured":"33. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011;18:1575\u201381.","DOI":"10.1245\/s10434-011-1631-5"},{"key":"2025120909210682132_j_pp-2016-0010_ref_034_w2aab3b7b4b1b6b1ab1b7c34Aa","doi-asserted-by":"crossref","unstructured":"34. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011;104:692\u20138.","DOI":"10.1002\/jso.22017"},{"key":"2025120909210682132_j_pp-2016-0010_ref_035_w2aab3b7b4b1b6b1ab1b7c35Aa","doi-asserted-by":"crossref","unstructured":"35. Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol 2014;21:1147\u201352.","DOI":"10.1245\/s10434-013-3443-2"},{"key":"2025120909210682132_j_pp-2016-0010_ref_036_w2aab3b7b4b1b6b1ab1b7c36Aa","doi-asserted-by":"crossref","unstructured":"36. Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, et al. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol 2014;21:1448\u201355.","DOI":"10.1245\/s10434-013-3327-5"},{"key":"2025120909210682132_j_pp-2016-0010_ref_037_w2aab3b7b4b1b6b1ab1b7c37Aa","unstructured":"37. Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, et al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol 2016 Jan 11."},{"key":"2025120909210682132_j_pp-2016-0010_ref_038_w2aab3b7b4b1b6b1ab1b7c38Aa","doi-asserted-by":"crossref","unstructured":"38. Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ. Safety of gastric resections during cytoreduction surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2009;16:2199\u201394.","DOI":"10.1245\/s10434-009-0478-5"},{"key":"2025120909210682132_j_pp-2016-0010_ref_039_w2aab3b7b4b1b6b1ab1b7c39Aa","doi-asserted-by":"crossref","unstructured":"39. Sugarbaker PH. Cytoreduction including total gastrectomy for psuedomxyoma peritoneii. Br J Surg 2002;89:208\u201312.","DOI":"10.1046\/j.0007-1323.2001.01967.x"},{"key":"2025120909210682132_j_pp-2016-0010_ref_040_w2aab3b7b4b1b6b1ab1b7c40Aa","doi-asserted-by":"crossref","unstructured":"40. Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006;106:1144\u201353.","DOI":"10.1002\/cncr.21708"},{"key":"2025120909210682132_j_pp-2016-0010_ref_041_w2aab3b7b4b1b6b1ab1b7c41Aa","doi-asserted-by":"crossref","unstructured":"41. Levine EA, Stewart 4th JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg 2007;204:943\u201353.","DOI":"10.1016\/j.jamcollsurg.2006.12.048"},{"key":"2025120909210682132_j_pp-2016-0010_ref_042_w2aab3b7b4b1b6b1ab1b7c42Aa","doi-asserted-by":"crossref","unstructured":"42. Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010;2(2):85\u201397.","DOI":"10.4251\/wjgo.v2.i2.85"},{"key":"2025120909210682132_j_pp-2016-0010_ref_043_w2aab3b7b4b1b6b1ab1b7c43Aa","doi-asserted-by":"crossref","unstructured":"43. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007 Nov 1;357(18):1810\u201320. Erratum in: N Engl J Med. 2008 May 1;358(18): 1977.","DOI":"10.1056\/NEJMoa072252"},{"key":"2025120909210682132_j_pp-2016-0010_ref_044_w2aab3b7b4b1b6b1ab1b7c44Aa","doi-asserted-by":"crossref","unstructured":"44. Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg 2014 Oct;219(4):664\u201375.","DOI":"10.1016\/j.jamcollsurg.2014.03.062"},{"key":"2025120909210682132_j_pp-2016-0010_ref_045_w2aab3b7b4b1b6b1ab1b7c45Aa","doi-asserted-by":"crossref","unstructured":"45. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003 Sep;90(9):1113\u201319. Article in North am surgical clinics.","DOI":"10.1002\/bjs.4164"},{"key":"2025120909210682132_j_pp-2016-0010_ref_046_w2aab3b7b4b1b6b1ab1b7c46Aa","doi-asserted-by":"crossref","unstructured":"46. Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003 Feb;27(2):153\u20138.","DOI":"10.1007\/s00268-002-6279-7"},{"key":"2025120909210682132_j_pp-2016-0010_ref_047_w2aab3b7b4b1b6b1ab1b7c47Aa","doi-asserted-by":"crossref","unstructured":"47. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for peritoneal recurrence in stage II\/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol 2012;19(5):1568\u201374.","DOI":"10.1245\/s10434-011-2158-5"},{"key":"2025120909210682132_j_pp-2016-0010_ref_048_w2aab3b7b4b1b6b1ab1b7c48Aa","doi-asserted-by":"crossref","unstructured":"48. D\u2018Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240(5):808\u201316.","DOI":"10.1097\/01.sla.0000143245.28656.15"},{"key":"2025120909210682132_j_pp-2016-0010_ref_049_w2aab3b7b4b1b6b1ab1b7c49Aa","doi-asserted-by":"crossref","unstructured":"49. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res 1996;82:53\u201363.","DOI":"10.1007\/978-1-4613-1247-5_4"},{"key":"2025120909210682132_j_pp-2016-0010_ref_050_w2aab3b7b4b1b6b1ab1b7c50Aa","doi-asserted-by":"crossref","unstructured":"50. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310\u201317.","DOI":"10.1200\/JCO.1989.7.9.1310"},{"key":"2025120909210682132_j_pp-2016-0010_ref_051_w2aab3b7b4b1b6b1ab1b7c51Aa","doi-asserted-by":"crossref","unstructured":"51. Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 2003;6(Suppl 1):45\u20139.","DOI":"10.1007\/s10120-003-0222-y"},{"key":"2025120909210682132_j_pp-2016-0010_ref_052_w2aab3b7b4b1b6b1ab1b7c52Aa","doi-asserted-by":"crossref","unstructured":"52. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized Phase III study of 5-fluorouracil continuous infusion vs sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol 2013;43:972\u201380.","DOI":"10.1093\/jjco\/hyt114"},{"key":"2025120909210682132_j_pp-2016-0010_ref_053_w2aab3b7b4b1b6b1ab1b7c53Aa","doi-asserted-by":"crossref","unstructured":"53. Hong SH, Shin YR, Roh SY, Jeon EK, Song KY, Park CH, et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer 2013;16:290\u2013300.","DOI":"10.1007\/s10120-012-0182-1"},{"key":"2025120909210682132_j_pp-2016-0010_ref_054_w2aab3b7b4b1b6b1ab1b7c54Aa","doi-asserted-by":"crossref","unstructured":"54. Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009 Dec;250(6):878\u201387.","DOI":"10.1097\/SLA.0b013e3181b21c7b"},{"key":"2025120909210682132_j_pp-2016-0010_ref_055_w2aab3b7b4b1b6b1ab1b7c55Aa","unstructured":"55. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011 Nov;254(5):684\u201393."},{"key":"2025120909210682132_j_pp-2016-0010_ref_056_w2aab3b7b4b1b6b1ab1b7c56Aa","doi-asserted-by":"crossref","unstructured":"56. K\u00f6nigsrainer I, Horvath P, Struller F, K\u00f6nigsrainer A, Beckert S. Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer 2014 Jun;14(2):117\u201322.","DOI":"10.5230\/jgc.2014.14.2.117"},{"key":"2025120909210682132_j_pp-2016-0010_ref_057_w2aab3b7b4b1b6b1ab1b7c57Aa","unstructured":"57. Spratt JS, Adcock RA, Muskovin M, Sherrill W, Mckeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256\u201360."},{"key":"2025120909210682132_j_pp-2016-0010_ref_058_w2aab3b7b4b1b6b1ab1b7c58Aa","unstructured":"58. Sugarbaker PH, Cunliffe WJ, Beliveau JF, de Bruin E, Graves T. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1988;1:66\u201379."},{"key":"2025120909210682132_j_pp-2016-0010_ref_059_w2aab3b7b4b1b6b1ab1b7c59Aa","unstructured":"59. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichlorophatinum(II) in intraperitoneal rat tumours after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380\u20134."},{"key":"2025120909210682132_j_pp-2016-0010_ref_060_w2aab3b7b4b1b6b1ab1b7c60Aa","doi-asserted-by":"crossref","unstructured":"60. Van de Vaart PJ, van der VAnge N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148\u201354.","DOI":"10.1016\/S0959-8049(97)00370-5"},{"key":"2025120909210682132_j_pp-2016-0010_ref_061_w2aab3b7b4b1b6b1ab1b7c61Aa","unstructured":"61. Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 1984;44:1840\u20136."},{"key":"2025120909210682132_j_pp-2016-0010_ref_062_w2aab3b7b4b1b6b1ab1b7c62Aa","unstructured":"62. Elias D, Detroz B, Debaene B, Damia E, Leclercq B, Rougier P, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology 1994;41:207\u201313."},{"key":"2025120909210682132_j_pp-2016-0010_ref_063_w2aab3b7b4b1b6b1ab1b7c63Aa","doi-asserted-by":"crossref","unstructured":"63. Zoetmulder FA. Cancer cell seeding during abdominal surgery: experimental studies. Cancer Treat Res 1996;82:155\u201361.","DOI":"10.1007\/978-1-4613-1247-5_10"},{"key":"2025120909210682132_j_pp-2016-0010_ref_064_w2aab3b7b4b1b6b1ab1b7c64Aa","unstructured":"64. Jacquet P, Elias D, Sugarbaker PH. Tumor implantation in cicatrization sites following surgery for digestive cancers. J Chir Paris 1996;133:175\u201382."},{"key":"2025120909210682132_j_pp-2016-0010_ref_065_w2aab3b7b4b1b6b1ab1b7c65Aa","doi-asserted-by":"crossref","unstructured":"65. Gonz\u00e1lez-Moreno S, Gonz\u00e1lez-Bay\u00f3n LA, Ortega-P\u00e9rez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2010;2:68\u201375.","DOI":"10.4251\/wjgo.v2.i2.68"},{"key":"2025120909210682132_j_pp-2016-0010_ref_066_w2aab3b7b4b1b6b1ab1b7c66Aa","doi-asserted-by":"crossref","unstructured":"66. Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis. Cancer 1977;39:2637\u201346.","DOI":"10.1002\/1097-0142(197706)39:6<2637::AID-CNCR2820390650>3.0.CO;2-S"},{"key":"2025120909210682132_j_pp-2016-0010_ref_067_w2aab3b7b4b1b6b1ab1b7c67Aa","doi-asserted-by":"crossref","unstructured":"67. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003;12:689\u2013701.","DOI":"10.1016\/S1055-3207(03)00029-2"},{"key":"2025120909210682132_j_pp-2016-0010_ref_068_w2aab3b7b4b1b6b1ab1b7c68Aa","doi-asserted-by":"crossref","unstructured":"68. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219\u201328.","DOI":"10.1016\/S1470-2045(04)01425-1"},{"key":"2025120909210682132_j_pp-2016-0010_ref_069_w2aab3b7b4b1b6b1ab1b7c69Aa","doi-asserted-by":"crossref","unstructured":"69. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy(IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65\u201373.","DOI":"10.1053\/ejso.2000.1033"},{"key":"2025120909210682132_j_pp-2016-0010_ref_070_w2aab3b7b4b1b6b1ab1b7c70Aa","doi-asserted-by":"crossref","unstructured":"70. McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2007;14:1105\u201313.","DOI":"10.1245\/s10434-006-9304-5"},{"key":"2025120909210682132_j_pp-2016-0010_ref_071_w2aab3b7b4b1b6b1ab1b7c71Aa","doi-asserted-by":"crossref","unstructured":"71. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:115\u201362.","DOI":"10.1245\/ASO.2003.03.067"},{"key":"2025120909210682132_j_pp-2016-0010_ref_072_w2aab3b7b4b1b6b1ab1b7c72Aa","doi-asserted-by":"crossref","unstructured":"72. Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:53\u20138.","DOI":"10.1016\/j.ejso.2004.09.011"},{"key":"2025120909210682132_j_pp-2016-0010_ref_073_w2aab3b7b4b1b6b1ab1b7c73Aa","doi-asserted-by":"crossref","unstructured":"73. Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2006;13:1627\u201332.","DOI":"10.1245\/s10434-006-9186-6"},{"key":"2025120909210682132_j_pp-2016-0010_ref_074_w2aab3b7b4b1b6b1ab1b7c74Aa","doi-asserted-by":"crossref","unstructured":"74. Passat G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol 2014;40(5):529\u201335.","DOI":"10.1016\/j.ejso.2013.11.019"},{"key":"2025120909210682132_j_pp-2016-0010_ref_075_w2aab3b7b4b1b6b1ab1b7c75Aa","doi-asserted-by":"crossref","unstructured":"75. Albertsmeier M, Hauer A, Niess H, Werner J, Graeb C, Angele MK. Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Dig Surg 2014;31:334\u201340.","DOI":"10.1159\/000369259"},{"key":"2025120909210682132_j_pp-2016-0010_ref_076_w2aab3b7b4b1b6b1ab1b7c76Aa","doi-asserted-by":"crossref","unstructured":"76. Tsilimparis N, Bockelmann C, Raue W, Menenakos C, Perez S, Rau B, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol 2013;20(1):226\u201332.","DOI":"10.1245\/s10434-012-2579-9"},{"key":"2025120909210682132_j_pp-2016-0010_ref_077_w2aab3b7b4b1b6b1ab1b7c77Aa","doi-asserted-by":"crossref","unstructured":"77. Duckworth KE, McQuellon RP, Russell GB, Cashwell CS, Shen P, Stewart 4th JH, et al. Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy(CS +HIPEC). J Surg Oncol 2012;106(4):376\u201380.","DOI":"10.1002\/jso.23089"},{"key":"2025120909210682132_j_pp-2016-0010_ref_078_w2aab3b7b4b1b6b1ab1b7c78Aa","doi-asserted-by":"crossref","unstructured":"78. Chia CS, Tan WJ, Wong JF, Tan GH, Lim C, Wang W, et al. Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2014;40(8):909\u201316.","DOI":"10.1016\/j.ejso.2013.12.028"},{"key":"2025120909210682132_j_pp-2016-0010_ref_079_w2aab3b7b4b1b6b1ab1b7c79Aa","doi-asserted-by":"crossref","unstructured":"79. Homma Y, Ushida S, Yamada M, Kobayashi H, Suzuki K. Positive peritoneal washing cytology in multiple cavities can predict poor prognosis of advanced gastric cancer patients. Ann Surg Oncol 2009;17(2):455\u201360.","DOI":"10.1245\/s10434-009-0764-2"},{"key":"2025120909210682132_j_pp-2016-0010_ref_080_w2aab3b7b4b1b6b1ab1b7c80Aa","unstructured":"80. Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operations for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for free cancer cells and a prophylactic strategy for peritoneal metastasis. Cling Cancer Res 2003;9(2):678\u201385."},{"key":"2025120909210682132_j_pp-2016-0010_ref_081_w2aab3b7b4b1b6b1ab1b7c81Aa","unstructured":"81. Edge S. Cancer AJCo: AJCC cancer staging manual, 7th ed. New York: Springer, 2010."},{"key":"2025120909210682132_j_pp-2016-0010_ref_082_w2aab3b7b4b1b6b1ab1b7c82Aa","doi-asserted-by":"crossref","unstructured":"82. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232\u20137.","DOI":"10.1002\/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U"},{"key":"2025120909210682132_j_pp-2016-0010_ref_083_w2aab3b7b4b1b6b1ab1b7c83Aa","doi-asserted-by":"crossref","unstructured":"83. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994;73:2048\u201352.","DOI":"10.1002\/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q"},{"key":"2025120909210682132_j_pp-2016-0010_ref_084_w2aab3b7b4b1b6b1ab1b7c84Aa","doi-asserted-by":"crossref","unstructured":"84. Fujimura T, Yonemura Y, Muraoka K, Takamura H, Hirono Y, Sahara H, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994;18:150\u20135.","DOI":"10.1007\/BF00348209"},{"key":"2025120909210682132_j_pp-2016-0010_ref_085_w2aab3b7b4b1b6b1ab1b7c85Aa","unstructured":"85. Ikeguchi M, Kondou A, Oka A, Tsujitani S, Maeta M, Kaibara N. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995;161:581\u20136."},{"key":"2025120909210682132_j_pp-2016-0010_ref_086_w2aab3b7b4b1b6b1ab1b7c86Aa","unstructured":"86. Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, et al. Intraperitoneal chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 2001;48:1776\u201382."},{"key":"2025120909210682132_j_pp-2016-0010_ref_087_w2aab3b7b4b1b6b1ab1b7c87Aa","doi-asserted-by":"crossref","unstructured":"87. Kim JY, Bae HS. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer 2001;4:27\u201333.","DOI":"10.1007\/s101200100013"},{"key":"2025120909210682132_j_pp-2016-0010_ref_088_w2aab3b7b4b1b6b1ab1b7c88Aa","doi-asserted-by":"crossref","unstructured":"88. Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multi enter phase III study. BMC Cancer 2014;14:183.","DOI":"10.1186\/1471-2407-14-183"},{"key":"2025120909210682132_j_pp-2016-0010_ref_089_w2aab3b7b4b1b6b1ab1b7c89Aa","doi-asserted-by":"crossref","unstructured":"89. Roviello F, Carusa S, Neri A, Marrelli D. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rational. Eur J Surg Oncol 2013;39:1309\u201316.","DOI":"10.1016\/j.ejso.2013.10.010"},{"key":"2025120909210682132_j_pp-2016-0010_ref_090_w2aab3b7b4b1b6b1ab1b7c90Aa","doi-asserted-by":"crossref","unstructured":"90. Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology 2010;78:40\u20136.","DOI":"10.1159\/000290955"},{"key":"2025120909210682132_j_pp-2016-0010_ref_091_w2aab3b7b4b1b6b1ab1b7c91Aa","unstructured":"91. Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S. S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis. Gastrointest Cancer Res 2012;5:S10\u20133."},{"key":"2025120909210682132_j_pp-2016-0010_ref_092_w2aab3b7b4b1b6b1ab1b7c92Aa","doi-asserted-by":"crossref","unstructured":"92. Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol 2014;21:539\u201346.","DOI":"10.1245\/s10434-013-3208-y"},{"key":"2025120909210682132_j_pp-2016-0010_ref_093_w2aab3b7b4b1b6b1ab1b7c93Aa","doi-asserted-by":"crossref","unstructured":"93. Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013;71:1265\u201372.","DOI":"10.1007\/s00280-013-2122-0"},{"key":"2025120909210682132_j_pp-2016-0010_ref_094_w2aab3b7b4b1b6b1ab1b7c94Aa","doi-asserted-by":"crossref","unstructured":"94. Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol 2011;18(13):3726\u201331.","DOI":"10.1245\/s10434-011-1770-8"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/2\/article-p67.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0010\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:47:58Z","timestamp":1765277278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0010\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":94,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6,9]]},"published-print":{"date-parts":[[2016,6,1]]}},"alternative-id":["10.1515\/pp-2016-0010"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0010","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}